Inve India ▾

Blue Jet Healthcare share price & results

Blue Jet Healthcare Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Specialty CDMO making contrast-media intermediates, high-intensity sweeteners, and pharma intermediates/APIs.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue293 ₹ crore−17.5% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin33.0 %−1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit78.0 ₹ crore−14.3% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equityUnavailable−19.9 ptsFY Mar 2021 vs FY Mar 2020Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow marginUnavailable−3.9 ptsFY Mar 2021 vs FY Mar 2020Fiscal yearFY · period unavailableNot in the analysed materials. No older figure is substituted.
Revenue growth (YoY)Unavailable—Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

4 of 8 judged targets kept · 14 open · verdicts reflect calls analysed to Q1 FY27.

Blue Jet Healthcare Limited management guidance track record on Inve: 22 targets tracked across analysed earnings calls (4 achieved, 4 missed, 14 open).

TargetOriginal wordingSaidLatest callVerdict
Gross Marginsomewhere around 53% to 55%
Call transcript, Q2 FY25 · 8 Nov 2024		Q2 FY25Q1 FY27:The reported gross margin for Q1 FY27 stood at 53%, which is within the guided range of 53% to 55%.
Call transcript, Q1 FY27 · 3 Aug 2026		Achieved
Annual EBITDA MarginSustain existing level (approx. 27-29%)
Call transcript, Q1 FY25 · 7 Aug 2024		Q1 FY25Q1 FY27:Q1 Operating EBITDA margin was 33.5%. No new annual guidance provided. The FY26 target was missed.
Call transcript, Q1 FY27 · 3 Aug 2026		Ghosted
Unit-3 Mahad CAPEXincrease to about Rs. 300 crores
Call transcript, Q1 FY26 · 22 Jul 2025		Q1 FY26Q1 FY27:We have invested already about INR210 crores on this project with a further INR40 crores committed in the next couple of months to complete this phase. This brings the total to INR 250 crores, a revision from the earlier INR 300 crores guidance.
Call transcript, Q1 FY27 · 3 Aug 2026		Revised Down

Source: Inve Guidance Tracker for Blue Jet Healthcare Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of Blue Jet Healthcare Limited's 22 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 19 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹495.55 +2.05% · +₹9.95

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −23.1% 1Y

₹300₹400₹500₹600₹700Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 4 Nov 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 25 May 2026Q1 FY27 — 3 Aug 2026

1Y: ₹644.7 on 24 Oct 2025 → ₹495.55. High ₹674.05 (3 Nov 2025), low ₹327.25 (30 Mar 2026).

Previous close
₹485.6
Market cap
₹9.2k Cr
52-week range
₹327.25 – ₹674.05
One year
−22.00%

Overview

Symbol
NSE:BLUEJET
Exchange
NSE
Currency
INR

What Blue Jet Healthcare Limited does

Based on the company's own presentations, annual report and earnings calls.

Blue Jet Healthcare is a specialty pharmaceutical and healthcare-ingredient company operating as an integrated Contract Development and Manufacturing Organisation (CDMO). It earns by supplying key starting and advanced chemical intermediates to global contrast-media manufacturers (for X-ray/CT and MRI imaging agents), by developing and manufacturing saccharin and its salts for high-intensity sweetener customers, and by producing pharma intermediates and APIs for innovator and multinational generic pharmaceutical companies in chronic therapy areas. Its business model is built on long-standing, multi-year supply relationships (4-27 years with some of the largest contrast-media manufacturers) and in-house R&D-led process development that lets it forward-integrate into higher-value advanced intermediates.

Segments

  • Contrast Media Intermediates
  • High-Intensity Sweeteners
  • Pharma Intermediates & APIs
  • Others
Manufacturing facilities
3 facilities across Shahad, Ambernath and Mahad, Maharashtra
Reaction capacity (FY26)
1,175.60 KL across 3 facilities
Commercialized products (FY26)
51 products — 19 contrast media, 4 high-intensity sweeteners, 28 pharma intermediates & API
Customers
350+ globally
Global reach
Presence across 50+ countries
R&D team
75+ scientists, PhDs and organic-chemistry specialists at the BlueJet Advance Research Centre (BARC), Unit II Ambernath
Founded 1968 Company website

How the price took the results

close before → close after

Q1 FY27
−5.9%
3 Aug
Q4 FY26
+9.1%
25 May
Q3 FY26
−10.0%
13 Feb
Q2 FY26
−10.0%
4 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Blue Jet Healthcare Limited

Free account: one company. Everything above stays public.

Write why you follow Blue Jet Healthcare Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Blue Jet Healthcare Limited

Guides on how to read this kind of business and the numbers that matter.